Evidence map›Paper›PMID 28799056›Full record

Trial reportThe journal of headache and pain2017

Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study.

Haifeng Zhang, Yajun Lian, Nanchang Xie, Chen Chen, Yake Zheng

Open access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The journal of headache and pain, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 6 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 6 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Haifeng ZhangDepartment of Neurology, First Affiliated Hospital of Zhengzhou University, 1 Jianshe East R, Zhengzhou City, HeNan Province, 450052, People's Republic of China.
Yajun LianDepartment of Neurology, First Affiliated Hospital of Zhengzhou University, 1 Jianshe East R, Zhengzhou City, HeNan Province, 450052, People's Republic of China. lianyajun840317@163.com.
Nanchang XieDepartment of Neurology, First Affiliated Hospital of Zhengzhou University, 1 Jianshe East R, Zhengzhou City, HeNan Province, 450052, People's Republic of China.
Chen ChenDepartment of Neurology, First Affiliated Hospital of Zhengzhou University, 1 Jianshe East R, Zhengzhou City, HeNan Province, 450052, People's Republic of China.
Yake ZhengDepartment of Neurology, First Affiliated Hospital of Zhengzhou University, 1 Jianshe East R, Zhengzhou City, HeNan Province, 450052, People's Republic of China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral RCT studies including ours, seem to prove the role of Botulinum toxin type A (BTX-A) in the treatment of trigeminal neuralgia (TN), but no standardized dosing regimen has been established. In our study, we compare two different methods of administration: single-dose or repeated-dose strategy which was most frequently applied over the years in our centre.

methodsAn open-label trail was conducted. One hundred patients with classic TN symptoms were recruited, and randomly and equally apportioned to single- or repeated-dose group. Patients in the single-dose group received a local BTX-A injection of 70 to 100 U. The repeated-dose group received an initial BTX-A injection of 50 to 70 U and then another of equal volume 2 weeks later. All patients were followed for 6 months.

resultsIn the single- and repeated-dose groups, 44 and 37, respectively, completed the entire study. The groups were statistically similar in TN frequency, time between treatment and effect, time to peak effect, VAS scores, and rates of adverse reactions (latency and duration). However, the single-dose group experienced significantly longer duration of effect (P = 0.032).

conclusionsThe single- and repeated-dosing BTX-A regimens were largely comparable in efficacy and safety. This study suggests that repeated dosing has no advantage over single dosing of BTX-A for TN. Dosing should be adjusted for the individual patient.

Indexed as

Acetylcholine Release InhibitorsBotulinum Toxins, Type ADose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPain MeasurementPilot ProjectsTrigeminal NeuralgiaAcetylcholine Release InhibitorsBotulinum Toxins, Type ABotulinum toxin type aRepeated dosingSingle dosingTrigeminal neuralgia

Identifiers

PMID28799056
PMCPMC5552618
OpenAlexW2745223142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.